指南与共识前列腺癌

临床局限性前列腺癌:AUA/ASTRO指南第一部分:引言、风险评估、分期与基于风险的管理

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management.
指南 / 共识 · J Urol · 2022-05-10

本指南为AUA/ASTRO临床局限性前列腺癌指南三部分系列的第一部分,由独立方法学顾问指导的系统综述支持,检索了Ovid MEDLINE、Cochrane CENTRAL和Cochrane系统评价数据库。本文详细阐述了风险评估、分期及基于风险的管理相关推荐条款,旨在为临床医生治疗临床局限性前列腺癌患者提供信息。

要点

  • 本指南为AUA/ASTRO临床局限性前列腺癌指南第一部分,聚焦风险评估、分期与基于风险的管理。
  • 指南声明基于证据和共识制定,系统综述由独立方法学顾问指导完成。
  • 未来试验的高质量证据对进一步改善此类患者照护至关重要。

核心结论

  • 本指南旨在为治疗临床局限性前列腺癌患者的临床医生提供信息。
  • 未来试验持续研究和发表高质量证据对进一步改善这些男性的照护至关重要。

研究设计与样本

  • 本指南由AUA/ASTRO临床局限性前列腺癌专家组制定,声明基于证据和共识。
  • 系统综述由独立方法学顾问指导,研究馆员检索了Ovid MEDLINE、Cochrane Central Register of Controlled Trials和Cochrane Database of Systematic Reviews。
  • 方法学团队补充检索了既往AUA综述纳入的研究及相关文章参考文献列表。

关键数值与推荐

  • 专家组制定了关于风险评估、分期和基于风险管理的指南声明,详见本文。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The summary presented herein represents Part I of the three-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment, staging, and risk-based management in patients diagnosed with clinically localized prostate cancer. Please refer to Parts II and III for discussion of principles of active surveillance, surgery and follow-up (Part II), and principles of radiation and future directions (Part III). MATERIALS AND METHODS: The systematic review utilized to inform this guideline was conducted by an independent methodological consultant. A research librarian conducted searches in Ovid MEDLINE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews. The methodology team supplemented searches of electronic databases with the studies included in the prior AUA review and by reviewing reference lists of relevant articles. RESULTS: The Clinically Localized Prostate Cancer Panel created evidence- and consensus-based guideline statements to aid clinicians in the management of patients with clinically localized prostate cancer. Statements regarding risk assessment, staging, and risk-based management are detailed herein. CONCLUSIONS: This guideline aims to inform clinicians treating patients with clinically localized prostate cancer. Continued research and publication of high-quality evidence from future trials will be essential to further improve care for these men.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol. 2022. PMID: 35536144. doi:10.1097/JU.0000000000002757

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。